Article Text

Download PDFPDF
OHP-013 Coronary stents in a regional hospital: Evolution and analysis from 2011 to 2015
  1. C Davoine1,
  2. A Guibert1,
  3. X Marchand2,
  4. A Durand1
  1. 1Centre Hospitalier Intercommunal de Poissy St Germain, Pharmacie, Poissy, France
  2. 2Centre Hospitalier Intercommunal de Poissy St Germain, Cardiologie, Poissy, France


Background One treatment for thromboembolic disease is transluminal angioplasty with stenting. There are currently two types of stents: bare metal stents (BMS) and drug eluting stents (DES).

Purpose Global analysis of the evolution between 2011 and 2015 of the number, type and indications for implantated stents in hospital.

Material and methods Data were collected between 2011 and July 2014 to June 2015 (ie, 12 months). The variables were: implanted stents (total, BMS, DES), number of patients and annual cost. A deeper analysis of stenting indications in 2011 compared with those in the 2014–2015 period was made. National data were included in the study.

Results In our hospital, 635 stents were implantated in 461 patients in 2011 and 864 in 604 patients in 2014–2015. Rate of DES increased from 39% to 76% in 4 years. In particular, DES with bioresorbable polymer increased from 25 in 2011 to 125 in 2014–2015. The total amount of stenting rose from 416 000€ to 516 000€. Analysis of indications between 2011 and 2014–2015 indicated: major development in stenting in diabetic patients (67 vs. 110); and increase in stenting in the management of intrastent restenosis (34 vs 47). The number of ‘off-label LPP’ (indications not provided by market authorisation) decreased from 18 stents in 2011 to 4 stents in 2014–2015. At the national level, 110 000 stents were implanted in 2011 vs. 132 000 in 2014–2015. Rate of DES dropped from 50% to 75%.

Conclusion This study has shown an increase in the number of stents and extension of the use of DES in our hospital, as well as at the national level. Indeed, DES have proven to be effective in practice in specific cases (diabetes, restenosis and artery dissection, for example). Prescribers were made aware to respect the recommendations, thanks to pharmaceutical follow-up including through prescription.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.